GUFICBIO2023-10-012023-12-31 GUFICBIO2023-10-012023-12-31 GUFICBIO2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member GUFICBIO2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member GUFICBIO2023-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 509079 GUFICBIO NOTLISTED Gufic Biosciences Limited Equity 2023-04-01 2024-03-31 2024-02-14 2024-02-07 INR Lakhs Third quarter 15:30:00 17:30:00 2024-02-14 2024-02-14 Not applicable Single segment The Company's business activity falls within a single operating segment i.e. Pharmaceuticals 2023-10-01 2023-12-31 Unaudited Standalone 2017779000.00 4236000.00 2022015000.00 729249000.00 119980000.00 104125000.00 306037000.00 31787000.00 41417000.00 393841000.00 1726436000.00 295579000.00 0.00 295579000.00 71977000.00 1031000.00 73008000.00 0.00 222571000.00 0.00 0.00 0.00 0.00 222571000.00 0.00 222571000.00 0.00 0.00 100278000.00 1 2.23 2.23 0.00 0.00 2.23 2.23 0.00 0.00 0.00 1. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of Companies Act, 2013, read with rules issued thereunder. 2. The above results for the quarter ended December 31, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 14, 2024.The Statutory Auditors have carried out limited review of the results for quarter and nine months ended December 31, 2023. 3. The Company's business activity falls within a single operating segment i.e. Pharmaceuticals. 4. The Company has incorporated Gufic UK Limited ( GUL ) in the United Kingdom on March 15, 2022, Gufic Ireland Limited ( GIL ) in Ireland on March 02, 2023 and Gufic Prime Private Limited (“GPPL”) in India on November 18, 2023, with the intention of making GUL and GIL its Wholly Owned Subsidiaries and GPPL as its Subsidiary Company. With respect to GIL and GPPL, as of December 31, 2023, neither investment have been made in GIL and GPPL nor they have begun their business operations. Consequently, there was no need to consolidate the accounts of GIL and GPPL with the Company. Whereas with respect to GUL, the Company on September 13, 2023, invested in GUL by subscribing to its shares. Therefore, the consolidated financial results for the quarter and nine months ending on December 31, 2023, have been prepared by the Company considering the financials of GUL. 5. Pursuant to the approval received from the Board of Directors, shareholders and the Stock Exchanges on which the shares of the Company are listed and in accordance with the applicable provision of Companies Act, 2013 and Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, the Board of Directors, on October 11, 2023, allotted 33,33,000 fully paid-up equity shares of the Company having face value of Rs. 1/- each, at the price of Rs. 300/- (Rupees Three Hundred Only) per equity share including premium of Rs. 299/- (Rupees Two Hundred Ninety-Nine Only) per equity share to M/s. Motilal Oswal Financial Services Limited, Non Promoter of the Company. 6. The equity shares and basic/diluted earnings per share for the comparative period (quarter and period ended December 31, 2023) has been presented in accordance with Ind AS-33 Earning per share. 7. Previous year/quarters figures have been regrouped/reclassified, wherever necessary. Single segment 2023-04-01 2023-12-31 Unaudited Standalone 6116722000.00 12958000.00 6129680000.00 2485963000.00 437198000.00 89639000.00 800230000.00 117125000.00 126751000.00 1187249000.00 5244155000.00 885525000.00 0.00 885525000.00 190705000.00 33924000.00 224629000.00 0.00 660896000.00 0.00 0.00 0.00 0.00 660896000.00 0.00 660896000.00 0.00 0.00 100278000.00 1 6.75 6.75 0.00 0.00 6.75 6.75 0.00 0.00 0.00 Other Expenses 393841000.00 Other Expenses 1187249000.00